Daiwa SB Investments sold its position in shares of Zoetis Inc (NYSE:ZTS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The hedge fund previously had a 27,140 share position in the company, valued at approximately $1,162,677. Daiwa SB Investments was fully divested from the company by the time it had filed its most recent disclosure with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Fulton Bank bought a new position in shares of Zoetis during the fourth quarter worth about $250,000. Janus Capital Management boosted its position in shares of Zoetis by 2.8% in the third quarter. Janus Capital Management now owns 7,471,338 shares of the company’s stock worth $307,670,000 after buying an additional 205,408 shares during the last quarter. Park National bought a new position in shares of Zoetis during the fourth quarter worth about $218,000. Eagle Asset Management boosted its position in shares of Zoetis by 44.0% in the third quarter. Eagle Asset Management now owns 212,242 shares of the company’s stock worth $8,740,000 after buying an additional 64,847 shares during the last quarter. Finally, Terra Nova Asset Management bought a new position in shares of Zoetis during the third quarter worth about $251,000.

Zoetis Inc (NYSE:ZTS) traded down 0.72% during trading on Thursday, reaching $42.84. The company had a trading volume of 5,660,560 shares. The stock has a 50 day moving average price of $45.89 and a 200 day moving average price of $45.56. The firm has a market capitalization of $21.33 billion and a P/E ratio of 48.68. Zoetis Inc has a 52 week low of $37.73 and a 52 week high of $55.38.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 3rd. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.10. The company had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.18 billion. During the same quarter in the prior year, the company earned $0.41 EPS. The firm’s quarterly revenue was up .3% on a year-over-year basis. Analysts predict that Zoetis Inc will post $1.73 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 1st. Shareholders of record on Thursday, January 21st will be issued a dividend of $0.095 per share. This is a positive change from Zoetis’s previous quarterly dividend of $0.08. The ex-dividend date is Tuesday, January 19th. This represents a $0.38 dividend on an annualized basis and a yield of 0.89%.

A number of research analysts have issued reports on the company. Jefferies Group lowered their price objective on Zoetis to $54.00 in a research note on Thursday, January 14th. Guggenheim reiterated a “buy” rating and set a $60.00 price objective on shares of Zoetis in a research note on Wednesday, January 13th. Cleveland Research assumed coverage on Zoetis in a research note on Friday, January 8th. They set a “buy” rating for the company. Argus reiterated a “buy” rating on shares of Zoetis in a research note on Sunday, January 3rd. Finally, Piper Jaffray reissued a “buy” rating and issued a $58.00 target price on shares of Zoetis in a report on Wednesday, December 16th. Three equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $53.96.

Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company markets products across four regions: the United States, Europe/Africa/Middle East, Canada/Latin America and Asia/Pacific; eight species: the livestock species of cattle, swine, poultry, sheep and fish, and the companion animal species of dogs, cats and horses, and five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceutical products. In addition, its Client Supply Services (NYSE:ZTS) organization provides contract manufacturing services to third parties.

12 Month Chart for NYSE:ZTS

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Zoetis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc and related companies with MarketBeat.com's FREE daily email newsletter.